This study involves the use of an investigational drug called NGP 555. In each group of healthy subjects, 2 people will receive placebo and 6 people will receive NGP 555.
Full record on ClinicalTrials.gov (NCT ID NCT02537938).
A Randomized, Placebo-Controlled, Double-blind, Parallel-Group, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Subjects
NeuroGenetic Pharmaceuticals Inc · Interventional, Randomized
12 views
★
★
★
★
★
Study context
Single-site study
Overview
Results summary
None
Outcome data
| Endpoint | Type | Result | Significance |
|---|---|---|---|
| Number of adverse events or safety outcomes | Primary | None | None |
Full results record on ClinicalTrials.gov.
Study design
- Phase
- Phase 1
- Study type
- Interventional
- Allocation
- Randomized
- Masking
- Quadruple-blind
- Intervention model
- Parallel assignment
- Primary purpose
- Prevention
- Enrollment (final)
- 24 participants
- Actually completed
- December 2016
Recruitment criteria
Age range: 40–65 · Sex: All · Healthy volunteers: Accepts
Locationsi
1 site participated during the trial period. Representative sites shown below; full historical record on ClinicalTrials.gov.
WCCT Global — Cypress, California (United States)
Sources
ClinicalTrials.gov — NCT02537938
Trial registry · primary record